SCHEMBL2800874

SCHEMBL2800874

CCOC(=O)c1cnn2c(Nc3ccc(C)cc3)c(C(=O)O)cnc12

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 7/20 0.56
KDM4E B2RXH2 7/20 0.56
NPC1 O15118 6/20 0.56
PDE4B Q07343 3/20 0.48
ALDH1A1 P00352 6/20 0.47
SMN1; SMN2 Q16637 5/20 0.47
NFKB1 P19838 2/20 0.47
NFKB2 Q00653 2/20 0.47
RELA Q04206 2/20 0.47
MAPT P10636 2/20 0.47
KDR P35968 1/20 0.47
MEN1 O00255 1/20 0.47
KMT2A Q03164 1/20 0.47
NPSR1 Q6W5P4 1/20 0.47
HPGD P15428 2/20 0.46
HSD17B10 Q99714 2/20 0.46
TP53 P04637 1/20 0.46
STAT1 P42224 1/20 0.46
HTT P42858 2/20 0.44
POLB P06746 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2800662 0.91 RAB9A (0.56) RAB9AKDM4ENPC1PDE4BALDH1A1
SCHEMBL2801709 0.88 KDR (0.57) RAB9AKDM4ENPC1PDE4BALDH1A1
SCHEMBL2800568 0.86 KDM4E (0.50) RAB9AKDM4ENPC1PDE4BALDH1A1
SCHEMBL2801353 0.85 KDM4E (0.52) RAB9AKDM4ENPC1PDE4BALDH1A1
SCHEMBL2801435 0.84 NPC1 (0.53) RAB9AKDM4ENPC1PDE4BALDH1A1
SCHEMBL2801447 0.84 KDM4E (0.50) RAB9AKDM4ENPC1PDE4BALDH1A1
SCHEMBL2799881 0.80 KDM4E (0.50) RAB9AKDM4ENPC1PDE4BALDH1A1
SCHEMBL2801494 0.80 CCNA2 (0.57) RAB9AKDM4ENPC1PDE4BALDH1A1
SCHEMBL2801479 0.79 KDR (0.57) RAB9AKDM4ENPC1PDE4BALDH1A1
SCHEMBL2800555 0.78 KDM4E (0.50) RAB9AKDM4ENPC1PDE4BALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2206714-B1 AGENT FOR PREVENTION AND/OR TREATMENT OF SKIN DISEASES KYOWA HAKKO KIRIN CO LTD (JP) 2015-01-21 EP disclosed
US-8729264-B2 Agent for prevention and/or treatment of skin diseases KYOWA HAKKO KIRIN CO., LTD. (JP) 2014-05-20 US disclosed
US-20100256134-A1 AGENT FOR PREVENTION AND/OR TREATMENT OF SKIN DISEASES KYOWA HAKKO KIRIN CO., LTD. (JP) 2010-10-07 US disclosed
EP-2206714-A1 AGENT FOR PREVENTION AND/OR TREATMENT OF SKIN DISEASES Kyowa Hakko Kirin Co., Ltd. (JP) 2010-07-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100256134-A1 AGENT FOR PREVENTION AND/OR TREATMENT OF SKIN DISEASES TYR, CUTA, SERPINB1 RAB9A 3259/4885KDM4E 3180/4885NPC1 1787/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.